OrthoPediatrics Corp.

OrthoPediatrics Corp. reported net revenue of $236.3 million for FY 2025, representing growth from $204.7 million in FY 2024. The company incurred a net loss of $39.6 million, an increase from a net loss of $37.8 million in the prior year. Gross profit was $172.7 million with a gross margin of 73.1%. Operating loss was $39.2 million, driven by total operating expenses of $211.9 million, which included significant sales and marketing ($72.7M) and general and administrative ($119.8M) costs, as well as restructuring ($5.6M) and intangible asset impairment ($4.6M) charges. The company ended the period with total assets of $508.6 million, total liabilities of $162.0 million, and stockholders' equity of $346.6 million. Net cash used in operating activities was $4.9 million, while net cash used in investing activities was $43.6 million, primarily for acquisitions and purchases of property and equipment. The company's growth was supported by strategic acquisitions and expansion into international markets, though it continues to face challenges in achieving profitability.

Key Takeaways